FIELD: medicine; ophthalmology.
SUBSTANCE: invention can be used to predict the risk of developing an unfavorable response to anti-VEGF therapy in macular neovascularization. Blood pressure is measured three times a day every day for one week. When systolic pressure is more than 138 mm Hg. and diastolic pressure more than 80 mm. Hg at least in one measurement an unfavorable response to anti-VEGF therapy is predicted.
EFFECT: invention provides the opportunity to increase the effectiveness of anti-VEGF therapy for macular neovascularization, due to a personalized approach to the indications for antiangiogenic therapy.
1 cl, 4 ex
